A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
Public ClinicalTrials.gov record NCT01170663. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Study identification
- NCT ID
- NCT01170663
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 665 participants
Conditions and interventions
Conditions
Interventions
- Ramucirumab (IMC-1211B) DP Biological
- Placebo Drug
- Paclitaxel Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2010
- Primary completion
- Jun 30, 2013
- Completion
- Jan 31, 2017
- Last update posted
- Sep 17, 2019
2010 – 2017
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ImClone Investigational Site | Burbank | California | 91505 | — |
| ImClone Investigational Site | Los Angeles | California | 90095 | — |
| ImClone Investigational Site | San Francisco | California | 94115 | — |
| ImClone Investigational Site | Jacksonville | Florida | 32207 | — |
| ImClone Investigational Site | Miramar | Florida | 33027 | — |
| ImClone Investigational Site | Atlanta | Georgia | 30322 | — |
| ImClone Investigational Site | Honolulu | Hawaii | 96813 | — |
| ImClone Investigational Site | East Orange | New Jersey | 07018 | — |
| ImClone Investigational Site | Albuquerque | New Mexico | 87131 | — |
| ImClone Investigational Site | New York | New York | 10016 | — |
| ImClone Investigational Site | Chattanooga | Tennessee | 37404 | — |
| ImClone Investigational Site | Houston | Texas | 77030 | — |
| ImClone Investigational Site | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 154 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01170663, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 17, 2019 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01170663 live on ClinicalTrials.gov.